DigestRedComo funciona
Red
/
Empresas
Ce
No verificado

Cellworks Group Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
08/09/2025
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Industria
Cellworks Unveils a Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
08/09/2025
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Eventos
Industria
Cellworks Study Reveals Tumor Microenvironment and TLS Dynamics Together Predict Patient-Level Immunotherapy Response in NSCLC
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
29/04/2025
Eventos
Industria
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Oncología
Cellworks’ Study Predicts Immune Checkpoint Inhibitor Resistance in Patients with High Microsatellite Instability
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
12/11/2024
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving Immunotherapy
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
16/09/2024
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Medicina - Varios
Farmacéutica
Salud
Oncología
Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC Patients
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
16/09/2024
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Oncología
Cellworks Biosimulation Predicts PARPi Benefit in Patients with Ovarian, Pancreatic, Prostate and Triple-Negative Breast Cancers
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
11/09/2024
Industria
Software
Ciencia
Farmacéutica
Oncología
Material médico sanitario
Técnica
Biotecnología
Medicina - Varios
Salud
Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0
09/09/2024
Industria
Biotecnología
Salud
Farmacéutica
Oncología
Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations
Fuente
Cellworks Group Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0